BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/5/2014 2:44:00 PM | Browse: 459 | Download: 530
Publication Name World Journal of Gastrointestinal Pharmacology and Therapeutics
Manuscript ID 4882
Country of Manuscript Source Spain
Received
2013-07-30 10:14
Peer-Review Started
2013-07-30 21:41
To Make the First Decision
2013-08-08 11:19
Return for Revision
2013-08-20 20:29
Revised
Second Decision
2013-12-10 16:37
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2013-12-11 10:06
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
2013-12-13 23:50
Typeset the Manuscript
2014-01-27 15:27
Publish the Manuscript Online
2014-01-27 17:26
ISSN 2150-5349 (online)
Open Access
Copyright
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Specialty Gastroenterology and Hepatology
Manuscript Type Minireviews
Article Title Aspirin, cyclooxygenase inhibition and colorectal cancer
Manuscript Source Invited Manuscript
All Author List Carlos Sostres, Carla Jerusalen Gargallo and Angel Lanas
Funding Agency and Grant Number
Funding Agency Grant Number
FIS P108/1301
AstraZeneca, Pfizer and Bayer (to Dr. Lanas A)
Corresponding author Angel Lanas, MD, DSc, Clinical Chief, Professor, Department of Digestive Diseases, University Hospital Lozano Blesa, c/Domingo Miral s/n, 50009 Zaragoza, Spain. alanas@unizar.es
Keywords Aspirin; Colorectal cancer; Cyclooxygenase inhibition; Mechanisms; Risk; Benefits
Core Tip Colorectal cancer (CRC) is a major cause of morbidity and mortality worldwide. Currently, CRC screening programs are not widely available and need to be improved. New prevention strategies are therefore necessary. Daily low-dose aspirin, as given for the prevention of cardiovascular disease events, has demonstrated benefits in clinical and basic studies in terms of preventing adenoma recurrence and decreasing the incidence of CRC and attributable mortality. These findings indicate that the antiplatelet action of aspirin plays a central role in its antitumor effect. Cyclooxygenase-dependent and independent mechanisms have been suggested to explain this effect. Extensive translational medical research is mandatory for future progress in CRC prevention.
Publish Date 2014-01-27 17:26
Citation Sostres C, Gargallo CJ, Lanas A. Aspirin, cyclooxygenase inhibition and colorectal cancer. World J Gastrointest Phar-macol Ther 2014; 5(1): 40-49
Url http://www.wjgnet.com/2150-5349/full/v5/i1/40.htm
DOI http://dx.doi.org/10.4292/wjgpt.v5.i1.40
Full Article (PDF) WJGPT-5-40.pdf
Full Article (Word) WJGPT-5-40.doc
Manuscript File 4882-Review.doc
Answering Reviewers 4882-Answering reviewers.pdf
Copyright License Agreement 4882-Copyright assignment.pdf
Peer-review Report 4882-Peer reviewer(s).pdf
Scientific Editor Work List 4882-Scientific editor work list.doc